Specificity |
Little or no interaction with natural beneficial microflora of the organism and environment |
Narrow host range; not useful in case of systemic disease |
Safety |
Action against AMR strains; ability to adapt to changing environmental conditions (e.g., phage-resistant bacteria); biofilms destruction |
Development of phage resistance; a risk of HTG; difficulty of lifecycle determination |
Stimulation of immune response |
Induction of immune response and resistance to bacterial infection |
Clearance of phages from the organism by immune system |
Formulation and administration |
Self-dosing, able to replicate in in vivo conditions |
A proper formulation needed to deliver bacteriophages to the site of infection |
Bacteriophage abundance and stability |
A lot of phages in the environment, easy to isolate, inexpensive |
Sensitivity to various physico-chemical parameters resulting in instability of phages |
Influence on the environment |
Non-toxicity to humans, plants, animals and environment |
Possibility of re-invasion of vacated niches by other bacterial species after eradication of pathogens |
Regulatory/economic aspects |
Growing research on phages in the entire world, a hope to replace antibiotics in a future |
Still many black holes in knowledge about phages; absence of regulatory guidelines to become regular treatment |